Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
21 hedge funds and large institutions have $10.8M invested in Medicenna Therapeutics Corp. Common Shares in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
34% more capital invested
Capital invested by funds: $8.1M → $10.8M (+$2.74M)
31% more funds holding
Funds holding: 16 → 21 (+5)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.81% more ownership
Funds ownership: 3.92% → 4.72% (+0.81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.17M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$176K |
| 3 |
TAM
Tocqueville Asset Management
New York
|
+$112K |
| 4 |
MCWS
McKinley Carter Wealth Services
Wheeling,
West Virginia
|
+$101K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$94.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$599K |
| 2 |
Renaissance Technologies
New York
|
-$401K |
| 3 |
VA
VR Adviser
New York
|
-$383K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$250K |
| 5 |
JP Morgan Chase
New York
|
-$73.1K |
MDNA Hedge Fund Activity: Q4 2020 in Review
21 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q4 2020, worth a combined $10.8M — up 34% from $8.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MDNA positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $2.17M. The largest seller was K2 Principal Fund, cutting an estimated $599K.
- 21 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q4 2020, up from 16 in Q3 2020.
- Funds reported $10.8M of Medicenna Therapeutics Corp. Common Shares stock for Q4 2020, up 34% quarter-over-quarter.
- 7 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q4 2020 and 2 closed out, a net change of +5 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q4 2020 was Verition Fund Management, an estimated $2.17M added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q4 2020 was K2 Principal Fund, an estimated $599K sold.
Based on aggregated 13F filings for Q4 2020.